Logo image
Ethosuximide-associated systemic lupus erythematosis in childhood
Journal article

Ethosuximide-associated systemic lupus erythematosis in childhood

James J. Riviello, Steven A. Raphael, Lawrence W. Brown and Donald P. Goldsmith
Journal of epilepsy, v 7(1), pp 23-26
1994

Abstract

Epilepsy Ethosuximide Pediatrics Systemic lupus erythematosis
Systemic lupus erythematosis (SLE) is an autoimmune disorder that may be associated with antiepileptic drugs (AEDs). The postulated mechanisms of drug-related lupus (DRL) include either an unmasking of idiopathic SLE or the actual induction of autoantibodies. Although ethosuximide (ETH) is one of the drugs most implicated in childhood DRL, our treatment of a 13-year-old girl with ETH-associated DRL prompted a literature search that revealed only 15 other cases. Many of these were on multiple AEDs. We subsequently became aware of two other cases. The relationship of ETH to SLE in these three children is discussed, and clinical and laboratory features useful in the differentiation of various types of SLE are reviewed.

Metrics

13 Record Views
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Logo image